Daihan Pharmaceutical Co.Ltd (023910) — Capital Reinvestment Ratio
Daihan Pharmaceutical Co.Ltd (023910) has a Capital Reinvestment Ratio of 1.14x as of September 2025, meaning it reinvests 1% of its operating cash flow (₩9.47 Billion) in capital expenditures (₩10.79 Billion). Check 023910 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Daihan Pharmaceutical Co.Ltd Capital Reinvestment Ratio (2014–2024)
This chart tracks Daihan Pharmaceutical Co.Ltd's Capital Reinvestment Ratio across 11 annual periods. For the full cash flow conversion analysis, see 023910 cash flow conversion.
Annual Capital Reinvestment Ratio for Daihan Pharmaceutical Co.Ltd (2014–2024)
Year-by-year Capital Reinvestment Ratio for Daihan Pharmaceutical Co.Ltd from 2014 to 2024. See free cash flow generation of Daihan Pharmaceutical Co.Ltd to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.44x | ₩35.64 Billion | ₩15.80 Billion | ▼ -19.0% |
| 2023 | 0.55x | ₩38.86 Billion | ₩21.28 Billion | ▲ +84.2% |
| 2022 | 0.30x | ₩29.00 Billion | ₩8.62 Billion | ▲ +1.9% |
| 2021 | 0.29x | ₩40.62 Billion | ₩11.85 Billion | ▲ +83.0% |
| 2020 | 0.16x | ₩33.63 Billion | ₩5.36 Billion | ▼ -67.5% |
| 2019 | 0.49x | ₩35.26 Billion | ₩17.30 Billion | ▼ -52.8% |
| 2018 | 1.04x | ₩44.94 Billion | ₩46.69 Billion | ▲ +1.0% |
| 2017 | 1.03x | ₩20.45 Billion | ₩21.05 Billion | ▲ +31.2% |
| 2016 | 0.78x | ₩27.92 Billion | ₩21.90 Billion | ▲ +255.8% |
| 2015 | 0.22x | ₩17.98 Billion | ₩3.96 Billion | ▼ -80.0% |
| 2014 | 1.10x | ₩9.48 Billion | ₩10.47 Billion | — |